{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:06:16Z","timestamp":1778918776032,"version":"3.51.4"},"reference-count":27,"publisher":"BMJ","issue":"e1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703479"],"award-info":[{"award-number":["81703479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taizhou Science and technology planning project","award":["1902ky194"],"award-info":[{"award-number":["1902ky194"]}]},{"name":"Wu Jieping Medical Foundation of Clinical Pharmacy Branch of Chinese Medical Association","award":["LCYX-Q012"],"award-info":[{"award-number":["LCYX-Q012"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2022,6,14]]},"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ejhpharm-2022-003357","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T17:25:47Z","timestamp":1656955547000},"page":"e90-e96","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients"],"prefix":"10.1136","volume":"30","author":[{"given":"QiaoWei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XuanLing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoMin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-9571","authenticated-orcid":false,"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"2024052713171442000_30.e1.e90.1","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000644"},{"key":"2024052713171442000_30.e1.e90.2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2024052713171442000_30.e1.e90.3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5414\/CP202078","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy","volume":"52","author":"Peng","year":"2014","journal-title":"CP"},{"key":"2024052713171442000_30.e1.e90.4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/01.ftd.0000179847.37965.4e","article-title":"Pharmacokinetic variability of new antiepileptic drugs at different ages","volume":"27","author":"Perucca","year":"2005","journal-title":"Ther Drug Monit"},{"key":"2024052713171442000_30.e1.e90.5","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024052713171442000_30.e1.e90.6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","article-title":"Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities","volume":"30","author":"Sugiyama","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"2024052713171442000_30.e1.e90.7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bcp.13400","article-title":"Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children","volume":"84","author":"van Dijkman","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2024052713171442000_30.e1.e90.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00124-3"},{"key":"2024052713171442000_30.e1.e90.9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.12659\/MSM.894023","article-title":"Abcb1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects","volume":"21","author":"Li","year":"2015","journal-title":"Med Sci Monit"},{"key":"2024052713171442000_30.e1.e90.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122043","article-title":"The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"2024052713171442000_30.e1.e90.11","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2014.00184","article-title":"Mdr-1 and MRP2 gene polymorphisms in Mexican epileptic pediatric patients with complex partial seizures","volume":"5","author":"Escalante-Santiago","year":"2014","journal-title":"Front Neurol"},{"key":"2024052713171442000_30.e1.e90.12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1684\/epd.2011.0443","article-title":"Association analysis of intractable epilepsy with C3435T and G2677T\/A ABCB1 gene polymorphisms in Iranian patients","volume":"13","author":"Sayyah","year":"2011","journal-title":"Epileptic Disord"},{"key":"2024052713171442000_30.e1.e90.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1405-1"},{"key":"2024052713171442000_30.e1.e90.14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jcpt.12792","article-title":"Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy","volume":"44","author":"Chen","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"2024052713171442000_30.e1.e90.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2600-8"},{"key":"2024052713171442000_30.e1.e90.16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/aps.2014.76","article-title":"Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"2024052713171442000_30.e1.e90.17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s13318-015-0266-5","article-title":"Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy","volume":"41","author":"Yu","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024052713171442000_30.e1.e90.18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-3252-8_4","article-title":"Simultaneous quantitation of lamotrigine, levetiracetam, 10-Hydroxycarbazepine, topiramate, and zonisamide in serum using HPLC-MS\/MS","volume":"1383","author":"Carlow","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2024052713171442000_30.e1.e90.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09687688.2019.1597194","article-title":"Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping","volume":"35","author":"Liu","year":"2019","journal-title":"Mol Membr Biol"},{"key":"2024052713171442000_30.e1.e90.20","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ejps.2017.05.034","article-title":"Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects","volume":"109S","author":"Antunes","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2024052713171442000_30.e1.e90.21","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424040-00001"},{"key":"2024052713171442000_30.e1.e90.22","unstructured":"Oxtellar XR . oxcarbazepine) [prescribing information. Rockville, MD: Supernus Pharmaceuticals, Inc, 2018 December."},{"key":"2024052713171442000_30.e1.e90.23","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00003"},{"key":"2024052713171442000_30.e1.e90.24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","article-title":"Effects of ABCB1, ABCC2, UGT2B7 and HNF4\u03b1 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy","volume":"51","author":"Shen","year":"2017","journal-title":"Seizure"},{"key":"2024052713171442000_30.e1.e90.25","first-page":"61","article-title":"Therapeutic drug monitoring of oxcarbazepine","volume":"65","author":"BOUQUIE","year":"2010","journal-title":"Therapie"},{"key":"2024052713171442000_30.e1.e90.26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/pgs.14.186","article-title":"Scn1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"key":"2024052713171442000_30.e1.e90.27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00228-016-2157-3","article-title":"Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy","volume":"73","author":"Lu","year":"2017","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T20:17:37Z","timestamp":1716841057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":27,"journal-issue":{"issue":"e1","published-online":{"date-parts":[[2023,3,19]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/ejhpharm-2022-003357"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003357","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]}}}